VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1] Summary by Relevant Sections Company Overview - Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is under investigation by Faruqi & Faruqi, LLP for potential violations of federal securities laws [1] Legal Action - A class action lawsuit has been filed against Vistagen, with a deadline for investors to seek lead plaintiff status set for March 16, 2026 [1] - The complaint alleges that Vistagen made false assertions about the success of fasedienol based on prior clinical trial results, which misled investors [1] Financial Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share [1]